Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 03:44:52 2024-06-12 pm EDT 		5-day change 1st Jan Change
25.88 USD +5.03% Intraday chart for Arrowhead Pharmaceuticals, Inc. +2.61% -15.36%
Jun. 03 Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise MT
Jun. 03 Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,686 4,405 6,509 3,498 2,880 3,059 - -
Enterprise Value (EV) 1 2,686 4,089 6,141 3,390 2,769 2,754 2,903 2,981
P/E ratio 40.8 x -51.3 x -45.9 x -19.8 x -14 x -7.85 x -9.16 x -10.5 x
Yield - - - - - - - -
Capitalization / Revenue 15.9 x 50.1 x 47.1 x 14.4 x 12 x 28.5 x 19.1 x 13.1 x
EV / Revenue 15.9 x 46.5 x 44.4 x 13.9 x 11.5 x 25.7 x 18.1 x 12.7 x
EV / EBITDA - -46.9 x -43.6 x -20.2 x -14.4 x -7.46 x -7.29 x -6.99 x
EV / FCF 16.7 x -38.1 x 41.6 x -17.9 x -8.38 x -5.64 x -13.3 x -11.1 x
FCF Yield 6% -2.63% 2.4% -5.57% -11.9% -17.7% -7.53% -9.01%
Price to Book - - 15.9 x 8.79 x 10.6 x 10.8 x 23.1 x 84 x
Nbr of stocks (in thousands) 95,301 102,292 104,259 105,849 107,193 124,200 - -
Reference price 2 28.18 43.06 62.43 33.05 26.87 24.64 24.64 24.64
Announcement Date 11/25/19 11/23/20 11/22/21 11/28/22 11/29/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 168.8 87.99 138.3 243.2 240.7 107.3 160.6 233.8
EBITDA 1 - -87.22 -140.8 -168.1 -192.5 -369.3 -398 -426.5
EBIT 1 61.19 -93.16 -149 -178.5 -205 -393.2 -385 -356
Operating Margin 36.25% -105.87% -107.77% -73.39% -85.16% -366.35% -239.77% -152.26%
Earnings before Tax (EBT) 1 61.19 -84.55 -140.8 -172.7 -206.5 -393.6 -345.4 -297.7
Net income 1 67.97 -84.55 -140.8 -176.1 -205.3 -360.5 -318.6 -297.7
Net margin 40.27% -96.09% -101.85% -72.39% -85.27% -335.86% -198.41% -127.29%
EPS 2 0.6900 -0.8400 -1.360 -1.670 -1.920 -3.138 -2.690 -2.350
Free Cash Flow 1 161 -107.3 147.7 -188.9 -330.6 -488.1 -218.6 -268.6
FCF margin 95.4% -121.99% 106.78% -77.67% -137.34% -454.76% -136.14% -114.89%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) 236.9% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 11/25/19 11/23/20 11/22/21 11/28/22 11/29/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 27.44 151.8 32.41 31.58 62.55 146.3 15.82 16.1 3.551 - 37.14 38.92 15.47 22.49 29.17
EBITDA 1 -60.75 44.15 -70.32 -81.17 -39.44 50.83 -99.43 -104.5 -132.3 - -1.8 -29.58 - - -
EBIT 1 -63.32 41.55 -72.91 -83.83 -42.13 48.16 -102.7 -108.3 -136.5 -126.2 -76.42 -76.68 -113.6 -114 -109.5
Operating Margin -230.77% 27.37% -224.94% -265.49% -67.36% 32.93% -648.99% -672.98% -3,845.25% - -205.75% -197.03% -734.19% -506.98% -375.29%
Earnings before Tax (EBT) 1 -62.87 44.37 -72.05 -82.16 -41.79 47.68 -103.4 -109 -138.7 -127 -80.38 -61.16 -100.5 -97.08 -106.4
Net income 1 -62.87 44.37 -72.05 -85.51 -41.81 47.68 -102.9 -109.7 -132.9 -125.3 -72.23 -48.86 -100.5 -97.08 -106.4
Net margin -229.13% 29.23% -222.28% -270.82% -66.85% 32.6% -650.53% -681.36% -3,741.59% - -194.47% -125.55% -649.81% -431.64% -364.67%
EPS 2 -0.6000 0.4100 -0.6800 -0.8100 -0.3900 0.4500 -0.9600 -1.020 -1.240 -1.020 -0.5752 -0.4752 -0.8424 -0.8432 -0.8142
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/2/22 5/10/22 8/4/22 11/28/22 2/6/23 5/2/23 8/7/23 11/29/23 2/6/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 315 368 108 111 305 157 77.6
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 161 -107 148 -189 -331 -488 -219 -269
ROE (net income / shareholders' equity) - - -14.6% -43.6% -61.3% -82.6% -147% -315%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 3.920 3.760 2.530 2.280 1.060 0.2900
Cash Flow per Share 2 - - - - - -1.680 - -
Capex 1 12 12 23.6 52.8 177 134 11.5 12.4
Capex / Sales 7.11% 13.58% 17.04% 21.7% 73.42% 124.48% 7.18% 5.3%
Announcement Date 11/25/19 11/23/20 11/22/21 11/28/22 11/29/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Arrowhead Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
24.64 USD
Average target price
52.43 USD
Spread / Average Target
+112.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARROWHEAD PHARMACEUTICALS, INC. Stock Arrowhead Pharmaceuticals, Inc.
-19.48% 3.06B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.34% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+15.06% 109B
BIONTECH SE Stock BioNTech SE
-6.39% 23.84B
ARGENX SE Stock argenx SE
+1.02% 22.42B
GENMAB A/S Stock Genmab A/S
-14.64% 17.5B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.64% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.07% 16.61B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.05% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+25.87% 11.47B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. Financials Arrowhead Pharmaceuticals, Inc.